Literature DB >> 33489132

Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake.

Takatsugu Ogata1, Yukiya Narita1, Kazunari Misawa2, Waki Hosoda3, Kei Muro1.   

Abstract

Although immune checkpoint inhibitors are commonly less effective for patients with a poor general condition, they can be effective and should be considered for poor general conditions in the case of MSI-H tumor.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  advanced gastric cancer; high microsatellite instability; immune checkpoint inhibitors; insufficient oral intake

Year:  2020        PMID： 33489132      PMCID： PMC7813093          DOI： 10.1002/ccr3.3399

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN： 2050-0904


  16 in total

1.  Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat.

Authors:  Kohei Shitara; Seiji Ito; Akira Sawaki; Masahiro Tajika; Hiroki Kawai; Tomoya Yokota; Daisuke Takahari; Takashi Ura; Kei Muro
Journal:  Oncology       Date:  2011-03-01       Impact factor: 2.935

2.  Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease.

Authors:  Noha Abdel-Wahab; Mohsin Shah; Maria A Lopez-Olivo; Maria E Suarez-Almazor
Journal:  Ann Intern Med       Date:  2018-07-17       Impact factor: 25.391

3.  Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).

Authors:  Kuniaki Shirao; Narikazu Boku; Yasuhide Yamada; Kensei Yamaguchi; Toshihiko Doi; Masahiro Goto; Junichiro Nasu; Tadamichi Denda; Yasuo Hamamoto; Atsuo Takashima; Haruhiko Fukuda; Atsushi Ohtsu
Journal:  Jpn J Clin Oncol       Date:  2013-09-07       Impact factor: 3.019

4.  Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.

Authors:  Yelena Y Janjigian; Francisco Sanchez-Vega; Philip Jonsson; Walid K Chatila; Jaclyn F Hechtman; Geoffrey Y Ku; Jamie C Riches; Yaelle Tuvy; Ritika Kundra; Nancy Bouvier; Efsevia Vakiani; Jianjiong Gao; Zachary J Heins; Benjamin E Gross; David P Kelsen; Liying Zhang; Vivian E Strong; Mark Schattner; Hans Gerdes; Daniel G Coit; Manjit Bains; Zsofia K Stadler; Valerie W Rusch; David R Jones; Daniela Molena; Jinru Shia; Mark E Robson; Marinela Capanu; Sumit Middha; Ahmet Zehir; David M Hyman; Maurizio Scaltriti; Marc Ladanyi; Neal Rosen; David H Ilson; Michael F Berger; Laura Tang; Barry S Taylor; David B Solit; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2017-11-09       Impact factor: 39.397

5.  Impact of modified FOLFOX-6 for patients with gastric cancer and a gastrointestinal obstruction.

Authors:  Hiroki Yukami; Tetsuji Terazawa; Masahiro Goto; Masahiko Aoki; Ken Asaishi; Toshifumi Yamaguchi; Shin Kuwakado; Takayuki Kii; Kazuhide Higuchi
Journal:  Asia Pac J Clin Oncol       Date:  2018-12-13       Impact factor: 2.601

6.  Systemic chemotherapy for peritoneal disseminated gastric cancer with inadequate oral intake: a retrospective study.

Authors:  Satoru Iwasa; Takako Eguchi Nakajima; Kenichi Nakamura; Atsuo Takashima; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Yasuhiro Shimada
Journal:  Int J Clin Oncol       Date:  2010-10-15       Impact factor: 3.402

7.  HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.

Authors:  Josef Rüschoff; Manfred Dietel; Gustavo Baretton; Susanne Arbogast; Axel Walch; Geneviéve Monges; Marie-Pierre Chenard; Frédérique Penault-Llorca; Iris Nagelmeier; Werner Schlake; H Höfler; H H Kreipe
Journal:  Virchows Arch       Date:  2010-07-28       Impact factor: 4.064

8.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.

Authors:  Seung Tae Kim; Razvan Cristescu; Adam J Bass; Kyoung-Mee Kim; Justin I Odegaard; Kyung Kim; Xiao Qiao Liu; Xinwei Sher; Hun Jung; Mijin Lee; Sujin Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Hyuk Lee; Mingew Choi; AmirAli Talasaz; Peter Soonmo Kang; Jonathan Cheng; Andrey Loboda; Jeeyun Lee; Won Ki Kang
Journal:  Nat Med       Date:  2018-07-16       Impact factor: 53.440

9.  Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.

Authors:  Hiroyuki Arai; Satoru Iwasa; Narikazu Boku; Masahiro Kawahira; Hirofumi Yasui; Toshiki Masuishi; Kei Muro; Keiko Minashi; Shuichi Hironaka; Naoki Fukuda; Daisuke Takahari; Takako Eguchi Nakajima
Journal:  BMC Cancer       Date:  2019-07-03       Impact factor: 4.430

10.  Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer.

Authors:  Masahiko Aoki; Hirokazu Shoji; Kengo Nagashima; Hiroshi Imazeki; Takahiro Miyamoto; Hidekazu Hirano; Yoshitaka Honma; Satoru Iwasa; Natsuko Okita; Atsuo Takashima; Ken Kato; Kazuhide Higuchi; Narikazu Boku
Journal:  ESMO Open       Date:  2019-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.